QoE & Sell-Side Prep for Med Spas
Med spas are having a moment with private equity, which is flattering right up until a buyer's accountant asks what happens to your revenue if the injector who has all the client relationships walks out the door. That question has a good answer — but only if your books can give it.
What a buyer is really paying for
A med-spa buyer is paying for a repeatable revenue engine, not a booked-out calendar this quarter. The value is in membership plans, the recurring cadence of injectables and treatments, the size and loyalty of the active-patient list, and how much of it survives if any single provider leaves. Recurring, provider-independent revenue earns the premium; a business that lives or dies by one charismatic injector does not.
There's also an accounting wrinkle buyers scrutinize: prepaid packages and memberships create deferred revenue — money collected for treatments not yet delivered. If that's booked as revenue on the day the card is swiped, your profit is overstated and diligence will find it. QoE prep gets the deferral right so the earnings you present are earnings you actually earned.
EBITDA is what the multiple attaches to, but for a med spa, key-person risk and revenue recognition decide whether a buyer trusts that EBITDA at all.
Add-backs and key-person risk
The usual legitimate add-backs apply — above-market owner comp, personal expenses run through the business, one-time build-out costs for a treatment room. Each raises adjusted EBITDA when documented well. But the swing factor unique to med spas is provider concentration: a buyer wants to see that revenue is spread across providers and tied to the brand and patient list, not to one person's phone.
We normalize owner and provider compensation to market, correct the deferred-revenue treatment, and quantify how revenue is distributed across providers — so the buyer's key-person worry is answered with data instead of reassurance.
How Kaizen runs it
We run a diligence-grade scan of your trailing twelve months, restate revenue into memberships versus one-time treatments, fix prepaid-package deferral, normalize owner and provider comp, and build the Reported-to-Adjusted EBITDA bridge a buyer's QoE firm will respect. You get a workbook, a narrative memo, and a clean-up list of the things to fix before the buyer's team finds them.
The goal: present a med spa whose revenue is recurring, correctly recognized, and bigger than any one provider — so diligence confirms the story instead of poking holes in it.
What's included
- Trailing-twelve-month Reported → Adjusted EBITDA bridge with support for every add-back
- Revenue restated into memberships/recurring treatments vs. one-time services and retail
- Prepaid-package and membership deferred revenue corrected to match delivery
- Owner and provider compensation normalized to market rates
- Provider concentration analyzed — how much revenue depends on any single injector
- Active-patient base and recurring cadence quantified (buyers ask — have the answer ready)
- Working-capital peg estimate so the closing true-up doesn't ambush you
- Narrative QoE memo plus a defensible workbook you can hand to advisors
Pricing
Straight answers
My whole business runs through prepaid packages — is that a problem?
Only if it's booked wrong. Prepaid treatments are deferred revenue until you deliver them; recognized correctly, they're a strength — proof of committed future demand. Recognized on the day you're paid, they overstate profit and hand diligence an easy adjustment. We fix the accounting so it works for you.
One injector drives most of my revenue. Does that kill the deal?
It caps the multiple, but it's not fatal — and pretending otherwise is worse. We quantify the concentration honestly so a buyer can price it, and so you can decide whether it's worth spreading revenue across providers before you sell.
Isn't this what the buyer's QoE firm does anyway?
They do it to protect the buyer, and their version discounts hard. Sell-side prep runs it first, on your side, so you set the anchor and they confirm it.
How far ahead of a sale should we start?
Ideally 6–12 months — enough time to fix the deferred-revenue accounting and, if needed, broaden how revenue is distributed across providers before a buyer's team looks.
Related
Free 20-minute books assessment
We'll show you the five things we'd fix first in your books — useful whether you hire us, hire someone, or do neither.
Talk to SalesOr call us directly: +1 786 789 0969